Literature DB >> 29424864

Prognostic factors in rectal cancer: where is the evidence?

Mehdi Khalfallah, Wejih Dougaz, Hichem Jerraya, Ramzi Nouira, Ibtissem Bouasker, Chadli Dziri.   

Abstract

BACKGROUND: In rectal cancer, the 5 years survival is about 53 % for all stages: it remains low in spite of the progress of diagnostic and therapeutic tools. The aim of this work was to provide evidence based answers to the following question: what are the pre, intra and post operative prognostic factors in rectal cancer?
METHODS: We have carried out a search in the following data bases: Pubmed, Embase, Cochrane and Scopus. The key words used were: « rectal cancer », « adenocarcinoma », « overall survival », « disease-free survival », « prognosis » and « evidence-based medicine ». The overall 5 years survival rate has been retained as primary outcome measure. Recurrence-free survival has been retained as secondary endpoint. Were included meta-analyses and systematic reviews of clinical trials dating back to less than six years.
RESULTS: We retrieved 270 publications, 27 articles only met the above-mentioned eligibility criteria and thereof have been retained in this work. A high operating volume, a specialized surgeon in colorectal surgery, a total mesorectal excision, an adjuvant chemotherapy given within no more than 8 weeks following the curative resection improve prognosis in rectal cancer with level I of evidence. Anastomotic leak and diabetes worsen prognosis in rectal cancer with level I of evidence. Margin of surgical resection must be RO to improve prognosis in rectal cancer with level I of evidence.
CONCLUSION: The main prognostic factors found in literature which we should keep in mind are those on which surgeons can  act:  neoadjuvant treatment,  high operating volume of the surgeon,  high tie of the inferior mesenteric  artery,  mesorectal excision , RO resection,  improvement of the techniques of intersphincteric resection and techniques of anastomosis   and adjuvant chemotherapy within less than 8 weeks when appropriate.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29424864

Source DB:  PubMed          Journal:  Tunis Med        ISSN: 0041-4131


  2 in total

1.  Can transrectal ultrasonography distinguish anorectal malignant melanoma from low rectal adenocarcinoma? A retrospective paired study for ten years.

Authors:  Jingwen Yan; Jigang Jing; Shuang Wu; Lacong Geiru; Hua Zhuang
Journal:  BMC Gastroenterol       Date:  2022-04-05       Impact factor: 3.067

2.  Construction of Nomogram-Based Prediction Model for Clinical Prognosis of Patients with Stage II and III Colon Cancer Who Underwent Xelox Chemotherapy after Laparoscopic Radical Resection.

Authors:  Qiang Sun; Kai Xu; Shifeng Teng; Wenqiang Wang; Wei Zhang; Xinxing Li; Zhiqian Hu
Journal:  J Oncol       Date:  2022-09-30       Impact factor: 4.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.